Lista de obras - Juan Pasquau - Dominio Público Uruguay

A review of the factors influencing antimicrobial prescribing

artículo científico

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.

artículo científico publicado en 2014

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

artículo científico publicado en 2018

Assisted reproductive technology and obstetric outcome in couples when the male partner has a chronic viral disease

artículo científico publicado en 2013

Budget Impact Analysis of Switching to Darunavir/Ritonavir Monotherapy for HIV-Infected People in Spain

artículo científico publicado el 1 de marzo de 2012

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study

artículo científico publicado en 2014

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.

artículo científico publicado en 2015

Disseminated infection with Mycobacterium avium complex in immunocompetent patients

artículo científico publicado en 2000

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri

artículo científico publicado en 2015

Duration of antimicrobial therapy

artículo científico publicado en 2015

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

artículo científico publicado en 2016

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.

artículo científico publicado en 2018

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

article

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

artículo científico publicado en 2014

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

artículo científico publicado en 2010

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.

artículo científico publicado en 2014

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

artículo científico publicado en 2016

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

artículo científico publicado en 2008

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

artículo científico publicado en 2017

High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era.

artículo científico publicado en 2017

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

artículo científico publicado en 2018

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

artículo científico publicado en 2001

Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia

artículo científico publicado en 2013

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

artículo científico publicado en 2011

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

artículo científico publicado en 2009

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

artículo científico publicado en 2008

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice

artículo científico publicado en 2014

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

scholarly article by Ignacio Pérez-Valero et al published 11 June 2018 in Journal of Antimicrobial Chemotherapy

Nuke-Sparing Regimens for the Long-Term Care of HIV Infection

artículo científico

Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain

artículo científico publicado en 2016

Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

artículo científico publicado en 2011

Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document

artículo científico publicado en 2011

Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy

artículo científico publicado en 2003

Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajos

artículo científico publicado en 2009

Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010-2016).

artículo científico publicado en 2017

Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

artículo científico publicado en 2009

Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)

artículo científico publicado en 2017

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

artículo científico publicado en 2015

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferio

artículo científico publicado en 2016

Study of human immunodeficiency virus transmission chains in Andalusia: analysis from baseline antiretroviral resistance sequences

artículo científico publicado en 2015

The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.

artículo científico publicado en 2015

The role of antimicrobial stewardship programs in the control of bacterial resistance

artículo científico publicado en 2016

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

article

[Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan].

artículo científico publicado en 2017

[Endocarditis due to Mycoplasma hominis]

artículo científico publicado en 2006

[Hafnia alvei bacteremia in an AIDS patient]

artículo científico publicado en 1997

Lista de obras de Juan Pasquau

A review of the factors influencing antimicrobial prescribing

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Assisted reproductive technology and obstetric outcome in couples when the male partner has a chronic viral disease

Budget Impact Analysis of Switching to Darunavir/Ritonavir Monotherapy for HIV-Infected People in Spain

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.

Disseminated infection with Mycobacterium avium complex in immunocompetent patients

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri

Duration of antimicrobial therapy

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era.

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

Nuke-Sparing Regimens for the Long-Term Care of HIV Infection

Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain

Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document

Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy

Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajos

Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010-2016).

Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferio

Study of human immunodeficiency virus transmission chains in Andalusia: analysis from baseline antiretroviral resistance sequences

The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.

The role of antimicrobial stewardship programs in the control of bacterial resistance

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

[Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan].

[Endocarditis due to Mycoplasma hominis]

[Hafnia alvei bacteremia in an AIDS patient]